IOVA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
121.5M
+22.3%
99.3M
+39.0%
71.4M
-17.7%
86.8M
+28.6%
67.5M
Cost of Revenue
48.0M
+10.2%
43.6M
+2.6%
42.5M
-1.4%
43.1M
+12.0%
38.5M
Gross Profit
73.4M
+31.8%
55.7M
+92.6%
28.9M
-33.7%
43.7M
+50.7%
29.0M
Operating Expenses
97.4M
-9.5%
107.6M
-2.1%
110.0M
-6.1%
117.1M
-5.5%
123.9M
R&D
49.3M
-16.2%
58.9M
-5.8%
62.5M
-12.2%
71.2M
-5.3%
75.2M
SG&A
38.6M
-1.8%
39.3M
+0.8%
38.9M
+7.0%
36.4M
+5.3%
34.6M
Operating Income
-23968000
+53.8%
-51905000
+36.0%
-81043000
-10.3%
-73460000
+22.6%
-94901000
EBITDA
-14470000
+65.9%
-42405000
+41.5%
-72504000
-14.1%
-63532000
+21.7%
-81162000
Net Income
-22271000
+52.9%
-47315000
+40.1%
-79045000
-9.9%
-71904000
+21.2%
-91253000
EPS (Basic)
$-0.05
+54.5%
$-0.11
+42.1%
$-0.19
-5.6%
$-0.18
+28.0%
$-0.25
EPS (Diluted)
$-0.05
+54.5%
$-0.11
+42.1%
$-0.19
-5.6%
$-0.18
+28.0%
$-0.25
Shares (Diluted)
455.9M
+1.3%
450.2M
+7.6%
418.5M
+2.6%
408.0M
+12.1%
364.0M
Iovance Biotherapeutics (IOVA) — Financials